Recruitment of Senior Scientist with Clinical PK/P

RNS Number : 8879U

Physiomics PLC

07 January 2013

 



Physiomics plc

("Physiomics") or ("the Company") 

Recruitment of Senior Scientist with Clinical PK/PD experience

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that Dr Hitesh Mistry has joined the Company as a Senior Scientist.

Dr Hitesh Mistry, Clinical PK/PD Modeller, has experience in modelling and simulation in the pharmaceutical industry from target identification (systems biology) to clinical development (population PKPD).  His work in early clinical oncology at AstraZeneca, building a translational disease model for Prostate Cancer, culminated in being awarded an AstraZeneca Oncology Innovation Award in 2012.  He was also involved in the development and deployment of AstraZeneca's first systems biology/pharmacology project in the cardiac toxicity area.   Dr Mistry will lead the development of Physiomics' flagship new product, Virtual Tumour Clinical and will also be involved in developing the company's cardiac toxicity model.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are extremely pleased to welcome Dr Mistry to our team. His unique mix of modelling, clinical and large pharma experience will be invaluable in the development of Virtual Tumour Clinical and for moving our collaborations firmly into the clinical space. This will allow access to a much larger market than the pre-clinical arena in which the Company currently operates."

Enquiries:

Physiomics plc                                                  

Mark Chadwick 

[phone]

WH Ireland Limited

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRALLFLELVISIIV